#MEDIA: Announcing results from a Phase 3 trial evaluating our investigational treatment for certain patients with EGFR-mutant non-squamous non-small cell lung cancer at #ESMO26. bit.ly/4jZfjc7
1
2
12
1,385
#MEDIA: We’re presenting results from a Phase 1 trial evaluating #CARTCellTherapy in multiple sclerosis (MS) at #MSToronto2026: bit.ly/47V3NqZ
0
1
8
1,017
#MEDIA: Announcing results from a Phase 3 trial evaluating our investigational treatment for certain adult patients with HR+/HER2- breast cancer at #ESMO26. bit.ly/4siOO3r
0
2
11
1,386
Pleased to share our investigational cancer asset was recently awarded Best ADC Clinical Impact during the 13th Annual ADC Awards. This recognition is encouraging, particularly as we approach #ESMO26 where we’ll be presenting data on our ADC asset: bit.ly/4i92P0d
0
2
7
1,328
#MEDIA: With 59 disclosures across lung cancer, breast cancer and other tumors with high unmet needs, we’re bringing the latest data from our oncology portfolio and pipeline to #ESMO26. bit.ly/4irVKI2
0
0
6
1,221
#MEDIA: Announcing positive topline results from the Phase 3 ACTION-1 trial of an investigational @RayzeBio therapy in people with GEP-NETs, a rare and difficult-to-treat cancer. An important step forward for patients with limited treatment options. bit.ly/4euDUld
1
7
24
4,557
#MEDIA: Today, we announced topline results from a Phase 3 trial for an investigational medicine for adults living with idiopathic pulmonary fibrosis. Read more: bit.ly/4ycc8RL
0
8
24
2,960
#MEDIA: Announcing positive topline results from a Phase 3 trial evaluating a novel oral combination regimen for adult patients with relapsed or refractory multiple myeloma, as early as first relapse. bit.ly/4jF3JT6
1
4
10
3,105
Healthcare professionals make an extraordinary difference every day. #ChampionsInCare is back, introducing a new $1 million community grant program for medically underserved communities. Together, we're building a world of gratitude. bit.ly/4rGexSV
0
1
9
1,452
#MEDIA: The U.S. FDA approved an expanded indication for our first-in-class treatment for adults and certain pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). bit.ly/4e53nkY
0
4
12
2,548
#MEDIA: Announcing first disclosure of results from a Phase 3 trial evaluating our treatment for certain adult patients with #MultipleMyeloma at #IMS26. bit.ly/4rPS1ax
2
3
20
3,652
#MEDIA: Today at #CCRWest2026, we announced two-year results from the Phase 3 study evaluating an approved medicine for adults with active #PsoriaticArthritis (PsA). Read more: bit.ly/4AnsaKQ
1
2
13
2,591
#MEDIA: Announcing positive topline results from a Phase 2 trial of an investigational #CARTCellTherapy for certain patients with relapsed or refractory multiple myeloma. bit.ly/4gJ1FYA
2
3
15
2,467
#MEDIA: At the 2026 #ESCCongress, we shared new long-term and real-world data in adults with symptomatic obstructive hypertrophic cardiomyopathy, adding to real-world evidence on long-term outcomes for this patient population: bit.ly/4yd4dEb
3
3
18
3,129
We're investing more than $173 million to expand U.S. radiopharmaceutical manufacturing capacity and help deliver next-generation cancer treatments to patients. Led by @RayzeBio, this investment will support jobs and innovation in Indiana. bit.ly/4qLAi3u #OneBMS
0
3
19
2,800
#MEDIA: @US_FDA granted accelerated approval to our new CELMoD treatment for relapsed or refractory #MultipleMyeloma in adults, introducing a new class of treatment. bit.ly/45s9hrO
4
8
27
6,457
For more than 25 years, the BMS Foundation, an independent charitable organization, has been strengthening health systems in Africa to address adult cancers as well as pediatric cancers and blood disorders. Read how our grantees are making an impact: bit.ly/4z66KkC
0
0
9
1,933
#MEDIA: Today, we announced a $2.3 billion investment to build a new manufacturing campus in Houston, Texas. Read more: bit.ly/45NIkyW
2
10
40
10,449
#MEDIA: The @US_FDA accepted a New Drug Application for our second oral investigational treatment for adult patients with relapsed or refractory multiple myeloma. bit.ly/4w5olaw
1
3
10
2,992
At the opening of our NYNJ World Cup 26 Jersey Fan Hub, our mascot Squibby brought the spirit of #BMSWontLose to New Jersey. See how we're standing shoulder to shoulder with our communities to advance progress during #FIFA2026 and beyond: bit.ly/4uHTTlk
5
2
12
8,616